Full Generic Medicine Info
Dosage/Direction for Use

Excessive mucus or sputum
Adult: Initially, 2,250 mg daily in divided doses, reduce to 1,500 mg daily when satisfactory response is obtained.
Child: 2-5 years 62.5-125 mg 4 times daily; 6-12 years 250 mg tid.
Should be taken with food.
Active peptic ulceration. Children <2 years.
Special Precautions
Patient with history of gastroduodenal ulcers, bronchospasm, asthma or respiratory failure. Debilitated patients. Children ≥2 years. Pregnancy and lactation.
Adverse Reactions
Significant: Gastrointestinal bleeding. Rarely, urticaria and bronchospasm. Immune system disorders: Anaphylactic reactions, fixed drug eruption. Gastrointestinal disorders: Nausea, vomiting, diarrhoea, gastric discomfort. Respiratory, thoracic and mediastinal disorders: Bronchorrhea. Skin and subcutaneous tissue disorders: Rashes. Rarely, bullous dermatitis (e.g. Stevens-Johnson syndrome, erythema multiforme).
Symptoms: Gastrointestinal disturbance (e.g. gastralgias, nausea, vomiting). Management: May perform gastric lavage, followed by observation.
Carbocisteine reduces goblet cell hyperplasia and therefore plays a role in the management of disorders characterised by abnormal mucous.
Absorption: Rapidly and well absorbed from the gastrointestinal tract. Time to peak plasma concentration: Approx 2 hours (range: 1-3 hours).
Distribution: Penetrates into lung tissue and respiratory mucous.
Metabolism: Metabolised in the liver via acetylation, decarboxylation and sulfoxidation.
Excretion: Via urine (as unchanged drug and metabolites). Elimination half-life: 1.87 hours (range: 1.4-2.5 hours).
Oral: Syrup: Store below 25°C. Tab/cap: Store below 30°C.
ATC Classification
R05CB03 - carbocisteine ; Belongs to the class of mucolytics. Used in the treatment of wet cough.
Disclaimer: This information is independently developed by CIMS based on carbocisteine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in